Going-concern and financing risk
The business requires external capital to fund R&D before product revenue exists.
- Scope
- Equity, debt, and partnership financing
- Materiality
- high
Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on developing therapies for rare genetic diseases, with exaluren as its lead product candidate. The company’s business model combines internal drug development with licensing and collaboration arrangements for selected programs.
−100,0 %
0.31
0.31
| % | |
|---|---|
| Clinical-stage product candidates | 70% Drug candidates in preclinical and clinical development for rare genetic diseases. |
| Licensing and collaboration income | 30% Upfront, milestone, and royalty economics from partnered development programs. |
Eloxx does not sell a broad commercial product portfolio; its economic counterparties are primarily pharmaceutical...
- Pharmaceutical collaboration partnersprimary
Partners such as Almirall that develop and commercialize licensed candidates and pay milestones/royalties.
- Rare-disease patients and treating physiciansprimary
Patients with inherited disorders such as nonsense mutation diseases, RDEB, and JEB who are the intended end users of therapies.
- Regulatory and clinical stakeholderssecondary
Agencies, investigators, and trial sites that enable clinical development and approval pathways.
Eloxx is headquartered in the United States and operates as a U.S.-based development-stage biotechnology company...
- •Headquartered in the United States
- •Clinical and regulatory focus spans the U.S., Japan, and Western Europe
- •Partnered program economics may come from global sales
- •Geographic exposure depends on trial enrollment and approval pathways
Eloxx’s strategy centers on advancing exaluren and other candidates through clinical development while preserving...
01
Advance lead clinical programsshort-term
Clinical progress is the main value driver for a development-stage biotech.
02
Secure external funding and partnershipsshort-term
Development programs require capital and can be supported through licensing economics.
03
Protect and expand intellectual propertymedium-term
Patent and know-how protection support partnering leverage and future commercialization value.
Eloxx faces the typical risks of a clinical-stage biotechnology company: trial failure, regulatory delay, and uncertain...
Clinical development failure or delay
The company’s value depends on advancing exaluren and other candidates through trials.
- Scope
- Exaluren and other pipeline programs
- Materiality
- high
Regulatory and approval risk
Rare-disease therapies require successful clinical and regulatory outcomes before commercialization.
- Scope
- FDA and other global regulators
- Materiality
- high
Partner dependency risk
Milestones and royalties depend on third-party development and commercialization decisions.
- Scope
- Almirall-licensed program and future collaborations
- Materiality
- medium
Research and development expense recognition
Quarterly operating loss volatility
Stock-based compensation valuation
Non-cash compensation expense
Warrants and financing instruments
Balance sheet and equity presentation
Going-concern assessment
Disclosure and investor interpretation of liquidity
ALX ONCOLOGY HOLDINGS INC
ALXO · Pharmaceutical Preparations
ALX Oncology Holdings Inc is a clinical-stage biotechnology company developing immuno-oncology therapies for cancer, headquartered in South San Francisco, California.
OCULAR THERAPEUTIX, INC
OCUL · Pharmaceutical Preparations
Scilex Holding Co
SCLX · Biological Products, (No Diagnostic Substances)
Scilex Holding Co is a U.S.-based biopharmaceutical company focused on non-opioid pain management and other specialty pharmaceutical products.
BiomX Inc.
PHGE · Biological Products, (No Diagnostic Substances)
CalciMedica, Inc.
CALC · Pharmaceutical Preparations
ELUTIA INC.
ELUT · Biological Products, (No Diagnostic Substances)
: 16/06/2026